


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))Docket No. 8-20-02
A0000417-01-CFP w/attach

In Re Application Of: JOSEPH ANTHONY CORNICELLI

Serial No.
10/071,034Filing Date
FEBRUARY 8, 2002Examiner
UNKNOWNGroup Art Unit
1623

Title: METHODS OF TREATING NUCLEAR FACTOR-KAPPA B MEDIATED DISEASES AND DISORDERS

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

AUG 06 2002

37 CFR 1.97(b)

TECH CENTER 1600/2900


1. ☒ ^{Supplemental} The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))Docket No.
A0000417-01-CFP

In Re Application: JOSEPH ANTHONY CORNICELLI

Serial No.
10/071,034Filing Date
FEBRUARY 8, 2002Patent Examiner
UNKNOWNGroup Art Unit
1623

METHODS OF TREATING NUCLEAR FACTOR-KAPPA B MEDIATED DISEASES AND

RECEIVED

AUG 06 2002

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

TECH CENTER 1600/2900

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 23-0455 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F	
_____ (Date)	
_____ Signature	
Typed or Printed Name of Person Signing Certificate	

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited July 29, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.	
Signature of Person Mailing Correspondence	
Nancy Dernbach	
Typed or Printed Name of Person Mailing Certificate	

*This certificate may only be used if paying by deposit account.

Signature

Dated: July 29, 2002

Claude F. Purchase, Jr.
Registration No. 47,871
Warner-Lambert Company
Patent Department
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-1692
Fax (734) 622-1553

CC:

+

are required to respond to the

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

1

6

2

10/071.034

February 8, 2002

Joseph Anthony Cornicelli

1623

Unknown

A0000417-01-CFP


[illegible][illegible]

Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/071,034
Filing Date	February 8, 2002
First Named Inventor	Joseph Anthony Cornicelli
Group Art Unit	1623
Examiner Name	Unknown
Attorney Docket Number	A0000417-01-CFP

RECEIVED

AUG 06 2002

TECH CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ROTH, Bruce D., et al, "Inhibitors of Acyl-CoA:Cholesterol Acyltransferase (ACAT). 15. Sulfonylurea Inhibitors With Excellent Hypocholesterolemic Activity, in Vivo", Bioorganic & Medicinal Chemistry Letters, Vol. 5, No. 20, 1995; pp 2367-2370; XP004135266; ISSN: 0960-894X	
		PICARD, Joseph A., "Inhibitors of Acyl-CoA:Cholesterol O -Acyltransferase. 17. Structure-Activity Relationships of Several Series of Compounds Derived from N-Chlorosulfonyl Isocyanate", J. Med. Chem., 1996, 39; pp 1243-1252; XP-001080050; ISSN: 0022-2623	
		BOCAN, Thomas M.A., "The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits", Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 20, No. 1, January, 2000; pp 70-79; XP000997385; ISSN:	
		DESFAITS, A. -C., et al, "Gliclazide reduces the induction of human monocyte adhesion to endothelial cells by glycated albumin", Diabetes, Obesity and Metabolism, Vol. 1, 1999; pp 113-120; XP-001080461; ISSN: 1462-8902	
		European Search Report for European Patent Application number EP 02 00 2612	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.